Reneo Pharmaceuticals Stock News

Reneo Pharmaceuticals Inc (RPHM) shares closed today 13.0% higher than it did at the end of yesterday. The stock is currently down 35.6% year-to-date, down 35.6% over the past 12 months, and down 35.6% over the past five years. Today, the Dow Jones Industrial Average rose 0.6%, and the S&P 500 rose 0.6%. Trading Activity Shares traded as high as $9.01 and as low as $6.55 this week.Shares closed 47.9% below its 52-week high and 50.4% above its 52-week low.Trading volume this week was 78.4% higher than the 10-day average and 115.1% higher than the 30-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 0.0. Technical Indicators The Relative Strength Index (RSI) on the stock was above 70, indicating it may be overbought.MACD, a trend-following momentum indicator, indicates an upward trend.The stock closed below its Bollinger band, indicating it may be oversold. Market Comparative Performance The company's share price beats the S&P 500 Index today, lags it on a 1-year basis, and lags it on a 5-year basis The company's share price beats the Dow Jones Industrial Average today, lags it on a 1-year basis, and lags it on a 5-year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by 24.0% The company's stock price performance over the past 12 months lags the peer average by 17.4% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

Reneo Pharmaceuticals Inc (RPHM) shares closed today 13.0% higher than it did at the end of yesterday. The stock is currently down 43.0% year-to-date, down 43.0% over the past 12 months, and down 43.0% over the past five years. Today, the Dow Jones Industrial Average rose 0.6%, and the S&P 500 rose 0.6%. Trading Activity Shares traded as high as $9.01 and as low as $6.55 this week.Shares closed 47.9% below its 52-week high and 50.4% above its 52-week low.Trading volume this week was 23.5% higher than the 10-day average and 132.1% higher than the 30-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 0.0. Technical Indicators The Relative Strength Index (RSI) on the stock was above 70, indicating it may be overbought.MACD, a trend-following momentum indicator, indicates an upward trend.The stock closed below its Bollinger band, indicating it may be oversold. Market Comparative Performance The company's share price beats the S&P 500 Index today, lags it on a 1-year basis, and lags it on a 5-year basis The company's share price beats the Dow Jones Industrial Average today, lags it on a 1-year basis, and lags it on a 5-year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by 47.5% The company's stock price performance over the past 12 months lags the peer average by 43.5% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

State Street Corp bought a new stake in shares of Reneo Pharmaceuticals, Inc. (NASDAQ:RPHM) in the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm bought 60,915 shares of the companys stock, valued at approximately $568,000. State Street Corp owned approximately 0.25% of Reneo Pharmaceuticals as of its []

Equities research analysts at LADENBURG THALM/SH SH began coverage on shares of Reneo Pharmaceuticals (NASDAQ:RPHM) in a research report issued to clients and investors on Monday, The Fly reports. The brokerage set a buy rating on the stock. Separately, Zacks Investment Research raised shares of Reneo Pharmaceuticals from a sell rating to a hold rating []

IRVINE, Calif., Oct. 11, 2021 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals, Inc. (NASDAQ: RPHM), a clinical-stage pharmaceutical company focused on the development and commercialization of therapies for

IRVINE, Calif., Sept. 28, 2021 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals, Inc. (NASDAQ: RPHM), a clinical stage pharmaceutical company focused on the development and commercialization of therapies for

IRVINE, Calif., Sept. 09, 2021 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals, Inc. (NASDAQ: RPHM), a clinical stage pharmaceutical company focused on the development and commercialization of therapies for

First patient dosed in STRIDE study of REN001 in primary mitochondrial myopathies First patient dosed in STRIDE study of REN001 in primary mitochondrial myopathies

SAN DIEGO, July 09, 2021 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals, Inc. (Nasdaq: RPHM), a clinical stage pharmaceutical company focused on the development and commercialization of therapies for patie

SAN DIEGO, May 20, 2021 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals, Inc. (NASDAQ: RPHM), a clinical stage pharmaceutical company focused on the development and commercialization of therapies for patien

SAN DIEGO, May 19, 2021 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals, Inc. (NASDAQ: RPHM), a clinical stage pharmaceutical company focused on the development and commercialization of therapies for patien

Just two IPOs priced this past week, raising $222 million as the US IPO market continued to cool down. The IPO pipeline remained active, with 13 IPOs and 14 SPACs submitting initial filings this week.

VectivBio Holding and Reneo Pharmaceuticals are making their market debuts on Nasdaq.

SAN DIEGO, April 08, 2021 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals, Inc., a clinical stage pharmaceutical company focused on the development and commercialization of therapies for patients with rare,